Financial

Financial Model and Investment Case

H-BMC icon

The Financial tier is where the H-BMC transitions from hypothesis to calculation. Unlike the tiers above — where each block requires discovery, testing, and iteration — the Financial tier blocks are derived from the assumptions established upstream. Cost Structure follows from Key Activities, Key Resources, and Key Partners. Revenue Stream follows from Market Size and Transaction Model. Investor Economics synthesizes both into the metrics investors use to evaluate whether the opportunity is fundable.

These blocks are descriptive, not prescriptive. The goal is not to teach financial modelling — it is to ensure teams understand what sophisticated investors and program officers will look for and can speak credibly to each metric. A weak financial model is almost always a symptom of unresolved hypotheses in the blocks above, not a modelling problem. Resolve those first.

Cost structures, revenue dynamics, and investor expectations differ meaningfully between HealthTech and Digital Medicine solutions. Select your solution type to see content relevant to your context.

My solution is:
13

Cost Structure

Financial Block — What It Costs to Operate the Model
Read This First

Cost Structure defines what it costs to deliver your value proposition and operate your business. It is a calculated output — it follows directly from the decisions made in Key Activities, Key Resources, and Key Partners. A team that has not yet resolved those blocks will not be able to produce a credible cost structure.

Cost structure is not static. It evolves significantly as the company moves from pre-revenue development through beachhead commercialization to target market scale. The most important discipline is understanding which costs are fixed and which are variable, and how that ratio changes over time.

Must Haves — Cost Structure
1
Fixed Costs Baseline expenses required to operate regardless of revenue or volume
2
Variable Costs Costs that scale with revenue and volume — the basis of gross margin
3
Customer Acquisition Cost (CAC) Total cost of sales and marketing required to close one new customer
4
Burn Rate and Runway Monthly cash consumption and how long current resources last

Must Haves

Fixed Costs
The baseline expenses required to operate the business regardless of revenue or volume. For a pre-revenue company, fixed costs typically dominate the cost structure and include core team salaries, facilities and equipment leases, regulatory and quality system maintenance, insurance, and basic administrative overhead. Fixed costs set the floor for monthly cash consumption before a single unit is sold. A company with high fixed costs and no revenue has limited time to reach its next fundable milestone.
Variable Costs
Costs that scale with revenue and volume. The ratio of variable costs to revenue — expressed as gross margin — is one of the most important metrics investors evaluate. A high gross margin signals that the business model is scalable. A low gross margin signals that profitability will require very high volume or significant cost reduction.
Customer Acquisition Cost (CAC)
The total cost of sales and marketing activity required to close one new customer. In healthcare, CAC is typically high — the sales cycle is long, the sales force is expensive, and clinical support and training add to the cost of bringing each institution to adoption. CAC must be evaluated against Customer Lifetime Value (LTV) — the total revenue generated by a customer over the duration of the relationship. A sustainable business model requires LTV to be significantly higher than CAC. A LTV:CAC ratio below 3:1 is typically considered insufficient for a scalable business.
Burn Rate and Runway
Burn rate is the net cash consumed per month after all revenues and expenses. Runway is how many months of operation current cash resources cover at the current burn rate. A team that does not know its burn rate and runway precisely is operating without one of the most basic instruments of financial management. Investors will ask for both in any serious funding conversation.

Nice to Haves — HealthTech

The medtech industry has reasonably well-established cost benchmarks that can serve as a sanity check on projections. Typical cost allocations for a commercializing medical device company are approximately: R&D 15-30%, Manufacturing 20-40%, Regulatory and Compliance 5-10%, Sales and Marketing 10-30%, Distribution and Logistics 5-15%, and G&A 10-20%. These ranges vary significantly by device category, regulatory pathway, and stage of commercialization — but a cost structure that falls far outside these ranges should be examined carefully.

A break-even analysis showing the revenue volume required to cover fixed costs — and at what level of market penetration the business becomes self-sustaining — helps validate whether the Target Market is large enough to support the business model. Sensitivity analysis showing how the cost structure changes if manufacturing costs are higher than projected or the sales cycle is longer than expected signals to investors that the team has stress-tested its assumptions.

Nice to Haves — Digital Medicine

Digital medicine cost structures differ significantly from medical devices. Typical allocations for an early-stage SaMD company are approximately: Software Development and AI/ML 30-45%, Regulatory and Clinical Validation 10-20%, Sales and Marketing 15-25%, Cloud Infrastructure and IT Security 5-15%, and G&A 10-15%. Manufacturing is near zero. Customer support costs can be significant if the solution requires ongoing clinical implementation support.

Because marginal costs for digital solutions approach zero at scale, a projection showing how gross margin improves as the fixed cost base is spread across a larger customer base is particularly compelling for digital medicine investors. For subscription-based solutions, a projection showing customer retention rates and their effect on net revenue retention is a standard investor expectation — customer churn has a compounding negative effect on the cost structure that device companies do not face.

14

Revenue Stream

Financial Block — How the Business Makes Money
Read This First

Revenue Stream is the calculated projection of income generated by your solution over time. It is not an independent estimate — it is the direct product of two blocks established above: Market Size and Transaction Model. If those two blocks are well-formed and evidence-based, Revenue Stream follows as a calculation. If they are not, no amount of financial modelling will produce a credible revenue projection.

Revenue Stream is a time-series estimate. It begins at zero, builds through beachhead penetration, and grows toward target market scale as adoption accelerates. The shape of the curve — how quickly revenue ramps, when it becomes meaningful, and what drives inflection points — is as important to investors as the eventual scale.

Must Haves — Revenue Stream
1
Beachhead Revenue Revenue from the initial target market at projected adoption rates
2
Target Market Revenue Revenue potential at full Target Market penetration — presented as a range
3
Revenue Growth Rate The projected rate at which revenue grows from beachhead to target market scale
4
Net Revenue Retention (NRR) Percentage of revenue retained from existing customers period to period

Must Haves

Beachhead Revenue
The revenue generated from your initial target market at projected adoption rates. This is the first test of whether the Transaction Model generates meaningful revenue at realistic market penetration. Investors evaluate beachhead revenue not for its size but for what it reveals about the revenue model's assumptions. A beachhead revenue projection that requires unrealistic adoption rates or pricing assumptions will be identified immediately.
Target Market Revenue
The revenue potential at full penetration of the Target Market, calculated as Relevant Entities × Usage Rate × Adoption Rate × Price per Transaction. This figure determines whether the business is worth building — it must be large enough to justify the capital investment required to reach it and to generate returns for investors. Target market revenue should be presented as a range reflecting conservative, base, and optimistic adoption scenarios rather than a single point estimate.
Revenue Growth Rate
The projected rate at which revenue grows from beachhead to target market scale, expressed as a compound annual growth rate (CAGR) or year-by-year trajectory. In medtech, revenue growth is typically slow in years one and two as the first institutional sales cycles complete, then accelerates as reference sites generate peer adoption. The growth rate projection must be grounded in realistic sales cycle assumptions from the Transaction Model — a hockey-stick revenue curve with no corresponding explanation of what drives the inflection is a credibility red flag.
Net Revenue Retention (NRR)
The percentage of revenue retained from existing customers from one period to the next, accounting for expansion, contraction, and churn. An NRR above 100% means existing customers are generating more revenue over time — through expanded use, additional units, or upselling — than is lost through cancellations or reductions. Investors in recurring revenue businesses consider NRR one of the most important indicators of business model health.

Nice to Haves — HealthTech

A waterfall chart showing how revenue builds from beachhead through target market — broken down by institution cohort and year of adoption — makes the growth trajectory tangible and testable. Investors can challenge specific cohort assumptions rather than the overall projection, which produces a more productive conversation.

A reimbursement timeline showing when CMS and private payor coverage is expected, and how each coverage decision affects the addressable market and pricing, is valuable for device and diagnostic companies where reimbursement is a gating factor for institutional adoption. Revenue projections that do not account for reimbursement timing are frequently unreliable.

Consumable attach rates — the ratio of consumable revenue to capital equipment placements over time — demonstrate the compounding revenue effect of the installed base and are a standard component of the revenue model for razor-and-blade business models.

Nice to Haves — Digital Medicine

Annual Recurring Revenue (ARR) and Monthly Recurring Revenue (MRR) projections are the standard revenue metrics for subscription-based digital medicine companies. Investors expect to see ARR broken down by new ARR (from new customers), expansion ARR (from existing customers upgrading or expanding), and churned ARR (from cancellations). This breakdown reveals the relative contribution of acquisition versus retention to revenue growth — a company growing ARR primarily through retention and expansion has a fundamentally more capital-efficient growth model than one growing only through new customer acquisition.

A cohort analysis showing the revenue trajectory of each annual customer cohort — how much they pay in year one and how that changes in years two and three — illustrates the long-term revenue value of each customer relationship and the compounding effect of retention. This is a standard expectation for digital health investors.

Customer payback period — the time it takes for revenue from a new customer to recover the cost of acquiring them — complements the LTV:CAC ratio and gives investors a sense of how capital-efficiently the business can scale. A payback period under 12 months is generally considered strong for a digital health subscription business.

15

Investor Economics

Financial Block — Margin, Unit Economics, and Return Potential
Read This First

Investor Economics synthesizes the business model into the metrics that investors use to evaluate whether the opportunity is worth funding. It is the block where the team must demonstrate not just that the product works and the market exists, but that the business can generate attractive returns for the capital required to build it.

Investor Economics is a time-series view. The metrics presented here will look very different at the seed stage, at Series A, and at the point of profitability. Investors evaluate not just where the numbers are today but the trajectory — whether the model is improving as the business scales and whether the team understands why.

Must Haves — Investor Economics
1
Gross Margin Revenue minus cost of goods sold — the primary indicator of business model quality
2
Unit Economics Revenue, cost, and margin at the level of a single transaction or customer
3
Capital Requirements Across All Stages Total capital to profitability, broken down by funding stage
4
Cap Table Current ownership structure and how this round affects dilution
5
Return Profile Expected exit pathway, valuation basis, and investor return potential

Must Haves

Gross Margin
Revenue minus cost of goods sold, expressed as a percentage of revenue. Gross margin is the primary indicator of business model quality and scalability. A high gross margin means that each incremental unit of revenue contributes significantly to covering fixed costs and generating profit. Medtech device companies typically target gross margins of 60-80% at scale. Digital medicine companies typically target 70-90%, reflecting the near-zero marginal cost of software delivery. Early-stage companies will have lower gross margins — what matters to investors is the trajectory and whether the model is capable of reaching benchmark levels as it scales.
Unit Economics
The revenue, cost, and margin generated by a single transaction, customer, or unit of use. Unit economics answer the fundamental question: does the business model work at the level of a single sale before worrying about scale? The key unit economics metrics are revenue per unit or customer, variable cost per unit or customer, contribution margin per unit or customer, and the LTV:CAC ratio. These must be presented consistently with the assumptions established in Market Size and Transaction Model. Investors will cross-check unit economics against those assumptions and flag any inconsistencies.
Capital Requirements Across All Stages
A projection of the total capital required to reach profitability, broken down by funding stage. The near-term capital requirement — the current round — should be a tight estimate tied to specific milestones: what will this capital achieve, what hypotheses will it test, and what evidence will it generate that justifies the next round at a higher valuation. Later-stage estimates are necessarily less precise but must be grounded in realistic assumptions about what each stage requires to achieve. A total capital to profitability estimate that is implausibly low signals that the team has not thought carefully about the full path. One that is implausibly high signals that the business model may not generate sufficient returns to justify the investment.
Cap Table
The current ownership structure of the company, showing who owns what percentage of equity — founders, employees, advisors, and investors — and what remains available in the option pool for future hires and investors. Investors evaluate the cap table to understand dilution history, founder commitment, and whether the ownership structure is clean enough to attract future rounds. A cap table with excessive early dilution of founders, missing option pool, or complicated ownership structures can make an otherwise attractive business model uninvestable. Teams should present their cap table clearly and be prepared to model how the current round affects ownership percentages at each subsequent funding stage.
Return Profile
An estimate of the financial return the business can generate for investors, expressed in terms of expected exit valuation, investor multiple, and exit pathway. Investors are typically deploying capital with the expectation of a 5-10x return within 7-10 years. The return profile must be grounded in realistic comparable transactions — what have similar companies sold for, what revenue or EBITDA multiples have recent exits commanded, and what acquirers are active in your category. A return profile that relies on an implausibly high exit valuation or an unrealistically short timeline will not be taken seriously by experienced investors.

Nice to Haves — HealthTech

A funding staircase diagram showing the capital requirements, key milestones, and expected valuation step-ups at each funding stage from current round through exit gives investors a visual representation of the full investment thesis. It signals that the team has thought carefully about the complete path to value creation and not just the immediate financing need.

Comparable transaction analysis — a table of recent acquisitions or IPOs of similar medical device or diagnostic companies showing exit valuations, revenue multiples, and acquirer identity — provides an evidence base for the return profile and demonstrates that the team understands the M&A landscape in their category.

A sensitivity table showing how investor returns change under different exit timing and valuation scenarios — what is the investor multiple if the company exits at 3x revenue vs 5x revenue, or at year 7 vs year 10 — gives investors the tools to evaluate the opportunity under their own assumptions rather than accepting the team's base case.

Nice to Haves — Digital Medicine

Rule of 40 analysis — the sum of revenue growth rate and profit margin, a standard benchmark for SaaS business model health — is an increasingly common metric among digital health investors. A Rule of 40 score above 40 signals that the business is balancing growth and profitability effectively. Early-stage companies will typically be well below 40, but demonstrating awareness of the metric and a credible path toward it signals financial sophistication.

SaaS valuation multiples — digital medicine companies are typically valued on ARR multiples rather than revenue or EBITDA multiples at the early stage. Understanding the current market range for ARR multiples in your category, and being able to explain what drives multiple expansion or compression, is a standard expectation in a digital health investor conversation.

A magic number analysis — measuring the efficiency of sales and marketing spend in generating new ARR — tells investors how capital-efficiently the business can scale its go-to-market motion. A magic number above 0.75 is generally considered healthy for a digital health subscription business and signals that increased investment in sales and marketing will generate proportionate returns.

Introduction · The Framework · The Blocks | Value Foundation · Stakeholder · Economic Model · Operations · Financial
ypothesis-forming">Hypothesis Forming Defining Markets The Blocks
Part 6 · The H-BMC Blocks

Financial

Financial Model and Investment Case

The Financial tier is where the H-BMC transitions from hypothesis to calculation. Unlike the tiers above — where each block requires discovery, testing, and iteration — the Financial tier blocks are derived from the assumptions established upstream. Cost Structure follows from Key Activities, Key Resources, and Key Partners. Revenue Stream follows from Market Size and Transaction Model. Investor Economics synthesizes both into the metrics investors use to evaluate whether the opportunity is fundable.

These blocks are descriptive, not prescriptive. The goal is not to teach financial modelling — it is to ensure teams understand what sophisticated investors and program officers will look for and can speak credibly to each metric. A weak financial model is almost always a symptom of unresolved hypotheses in the blocks above, not a modelling problem. Resolve those first.

Cost structures, revenue dynamics, and investor expectations differ meaningfully between HealthTech and Digital Medicine solutions. Select your solution type to see content relevant to your context.

My solution is:
13

Cost Structure

Financial Block — What It Costs to Operate the Model
Read This First

Cost Structure defines what it costs to deliver your value proposition and operate your business. It is a calculated output — it follows directly from the decisions made in Key Activities, Key Resources, and Key Partners. A team that has not yet resolved those blocks will not be able to produce a credible cost structure.

Cost structure is not static. It evolves significantly as the company moves from pre-revenue development through beachhead commercialization to target market scale. The most important discipline is understanding which costs are fixed and which are variable, and how that ratio changes over time.

Must Haves — Cost Structure
1
Fixed Costs Baseline expenses required to operate regardless of revenue or volume
2
Variable Costs Costs that scale with revenue and volume — the basis of gross margin
3
Customer Acquisition Cost (CAC) Total cost of sales and marketing required to close one new customer
4
Burn Rate and Runway Monthly cash consumption and how long current resources last

Must Haves

Fixed Costs
The baseline expenses required to operate the business regardless of revenue or volume. For a pre-revenue company, fixed costs typically dominate the cost structure and include core team salaries, facilities and equipment leases, regulatory and quality system maintenance, insurance, and basic administrative overhead. Fixed costs set the floor for monthly cash consumption before a single unit is sold. A company with high fixed costs and no revenue has limited time to reach its next fundable milestone.
Variable Costs
Costs that scale with revenue and volume. The ratio of variable costs to revenue — expressed as gross margin — is one of the most important metrics investors evaluate. A high gross margin signals that the business model is scalable. A low gross margin signals that profitability will require very high volume or significant cost reduction.
Customer Acquisition Cost (CAC)
The total cost of sales and marketing activity required to close one new customer. In healthcare, CAC is typically high — the sales cycle is long, the sales force is expensive, and clinical support and training add to the cost of bringing each institution to adoption. CAC must be evaluated against Customer Lifetime Value (LTV) — the total revenue generated by a customer over the duration of the relationship. A sustainable business model requires LTV to be significantly higher than CAC. A LTV:CAC ratio below 3:1 is typically considered insufficient for a scalable business.
Burn Rate and Runway
Burn rate is the net cash consumed per month after all revenues and expenses. Runway is how many months of operation current cash resources cover at the current burn rate. A team that does not know its burn rate and runway precisely is operating without one of the most basic instruments of financial management. Investors will ask for both in any serious funding conversation.

Nice to Haves — HealthTech

The medtech industry has reasonably well-established cost benchmarks that can serve as a sanity check on projections. Typical cost allocations for a commercializing medical device company are approximately: R&D 15-30%, Manufacturing 20-40%, Regulatory and Compliance 5-10%, Sales and Marketing 10-30%, Distribution and Logistics 5-15%, and G&A 10-20%. These ranges vary significantly by device category, regulatory pathway, and stage of commercialization — but a cost structure that falls far outside these ranges should be examined carefully.

A break-even analysis showing the revenue volume required to cover fixed costs — and at what level of market penetration the business becomes self-sustaining — helps validate whether the Target Market is large enough to support the business model. Sensitivity analysis showing how the cost structure changes if manufacturing costs are higher than projected or the sales cycle is longer than expected signals to investors that the team has stress-tested its assumptions.

Nice to Haves — Digital Medicine

Digital medicine cost structures differ significantly from medical devices. Typical allocations for an early-stage SaMD company are approximately: Software Development and AI/ML 30-45%, Regulatory and Clinical Validation 10-20%, Sales and Marketing 15-25%, Cloud Infrastructure and IT Security 5-15%, and G&A 10-15%. Manufacturing is near zero. Customer support costs can be significant if the solution requires ongoing clinical implementation support.

Because marginal costs for digital solutions approach zero at scale, a projection showing how gross margin improves as the fixed cost base is spread across a larger customer base is particularly compelling for digital medicine investors. For subscription-based solutions, a projection showing customer retention rates and their effect on net revenue retention is a standard investor expectation — customer churn has a compounding negative effect on the cost structure that device companies do not face.

14

Revenue Stream

Financial Block — How the Business Makes Money
Read This First

Revenue Stream is the calculated projection of income generated by your solution over time. It is not an independent estimate — it is the direct product of two blocks established above: Market Size and Transaction Model. If those two blocks are well-formed and evidence-based, Revenue Stream follows as a calculation. If they are not, no amount of financial modelling will produce a credible revenue projection.

Revenue Stream is a time-series estimate. It begins at zero, builds through beachhead penetration, and grows toward target market scale as adoption accelerates. The shape of the curve — how quickly revenue ramps, when it becomes meaningful, and what drives inflection points — is as important to investors as the eventual scale.

Must Haves — Revenue Stream
1
Beachhead Revenue Revenue from the initial target market at projected adoption rates
2
Target Market Revenue Revenue potential at full Target Market penetration — presented as a range
3
Revenue Growth Rate The projected rate at which revenue grows from beachhead to target market scale
4
Net Revenue Retention (NRR) Percentage of revenue retained from existing customers period to period

Must Haves

Beachhead Revenue
The revenue generated from your initial target market at projected adoption rates. This is the first test of whether the Transaction Model generates meaningful revenue at realistic market penetration. Investors evaluate beachhead revenue not for its size but for what it reveals about the revenue model's assumptions. A beachhead revenue projection that requires unrealistic adoption rates or pricing assumptions will be identified immediately.
Target Market Revenue
The revenue potential at full penetration of the Target Market, calculated as Relevant Entities × Usage Rate × Adoption Rate × Price per Transaction. This figure determines whether the business is worth building — it must be large enough to justify the capital investment required to reach it and to generate returns for investors. Target market revenue should be presented as a range reflecting conservative, base, and optimistic adoption scenarios rather than a single point estimate.
Revenue Growth Rate
The projected rate at which revenue grows from beachhead to target market scale, expressed as a compound annual growth rate (CAGR) or year-by-year trajectory. In medtech, revenue growth is typically slow in years one and two as the first institutional sales cycles complete, then accelerates as reference sites generate peer adoption. The growth rate projection must be grounded in realistic sales cycle assumptions from the Transaction Model — a hockey-stick revenue curve with no corresponding explanation of what drives the inflection is a credibility red flag.
Net Revenue Retention (NRR)
The percentage of revenue retained from existing customers from one period to the next, accounting for expansion, contraction, and churn. An NRR above 100% means existing customers are generating more revenue over time — through expanded use, additional units, or upselling — than is lost through cancellations or reductions. Investors in recurring revenue businesses consider NRR one of the most important indicators of business model health.

Nice to Haves — HealthTech

A waterfall chart showing how revenue builds from beachhead through target market — broken down by institution cohort and year of adoption — makes the growth trajectory tangible and testable. Investors can challenge specific cohort assumptions rather than the overall projection, which produces a more productive conversation.

A reimbursement timeline showing when CMS and private payor coverage is expected, and how each coverage decision affects the addressable market and pricing, is valuable for device and diagnostic companies where reimbursement is a gating factor for institutional adoption. Revenue projections that do not account for reimbursement timing are frequently unreliable.

Consumable attach rates — the ratio of consumable revenue to capital equipment placements over time — demonstrate the compounding revenue effect of the installed base and are a standard component of the revenue model for razor-and-blade business models.

Nice to Haves — Digital Medicine

Annual Recurring Revenue (ARR) and Monthly Recurring Revenue (MRR) projections are the standard revenue metrics for subscription-based digital medicine companies. Investors expect to see ARR broken down by new ARR (from new customers), expansion ARR (from existing customers upgrading or expanding), and churned ARR (from cancellations). This breakdown reveals the relative contribution of acquisition versus retention to revenue growth — a company growing ARR primarily through retention and expansion has a fundamentally more capital-efficient growth model than one growing only through new customer acquisition.

A cohort analysis showing the revenue trajectory of each annual customer cohort — how much they pay in year one and how that changes in years two and three — illustrates the long-term revenue value of each customer relationship and the compounding effect of retention. This is a standard expectation for digital health investors.

Customer payback period — the time it takes for revenue from a new customer to recover the cost of acquiring them — complements the LTV:CAC ratio and gives investors a sense of how capital-efficiently the business can scale. A payback period under 12 months is generally considered strong for a digital health subscription business.

15

Investor Economics

Financial Block — Margin, Unit Economics, and Return Potential
Read This First

Investor Economics synthesizes the business model into the metrics that investors use to evaluate whether the opportunity is worth funding. It is the block where the team must demonstrate not just that the product works and the market exists, but that the business can generate attractive returns for the capital required to build it.

Investor Economics is a time-series view. The metrics presented here will look very different at the seed stage, at Series A, and at the point of profitability. Investors evaluate not just where the numbers are today but the trajectory — whether the model is improving as the business scales and whether the team understands why.

Must Haves — Investor Economics
1
Gross Margin Revenue minus cost of goods sold — the primary indicator of business model quality
2
Unit Economics Revenue, cost, and margin at the level of a single transaction or customer
3
Capital Requirements Across All Stages Total capital to profitability, broken down by funding stage
4
Cap Table Current ownership structure and how this round affects dilution
5
Return Profile Expected exit pathway, valuation basis, and investor return potential

Must Haves

Gross Margin
Revenue minus cost of goods sold, expressed as a percentage of revenue. Gross margin is the primary indicator of business model quality and scalability. A high gross margin means that each incremental unit of revenue contributes significantly to covering fixed costs and generating profit. Medtech device companies typically target gross margins of 60-80% at scale. Digital medicine companies typically target 70-90%, reflecting the near-zero marginal cost of software delivery. Early-stage companies will have lower gross margins — what matters to investors is the trajectory and whether the model is capable of reaching benchmark levels as it scales.
Unit Economics
The revenue, cost, and margin generated by a single transaction, customer, or unit of use. Unit economics answer the fundamental question: does the business model work at the level of a single sale before worrying about scale? The key unit economics metrics are revenue per unit or customer, variable cost per unit or customer, contribution margin per unit or customer, and the LTV:CAC ratio. These must be presented consistently with the assumptions established in Market Size and Transaction Model. Investors will cross-check unit economics against those assumptions and flag any inconsistencies.
Capital Requirements Across All Stages
A projection of the total capital required to reach profitability, broken down by funding stage. The near-term capital requirement — the current round — should be a tight estimate tied to specific milestones: what will this capital achieve, what hypotheses will it test, and what evidence will it generate that justifies the next round at a higher valuation. Later-stage estimates are necessarily less precise but must be grounded in realistic assumptions about what each stage requires to achieve. A total capital to profitability estimate that is implausibly low signals that the team has not thought carefully about the full path. One that is implausibly high signals that the business model may not generate sufficient returns to justify the investment.
Cap Table
The current ownership structure of the company, showing who owns what percentage of equity — founders, employees, advisors, and investors — and what remains available in the option pool for future hires and investors. Investors evaluate the cap table to understand dilution history, founder commitment, and whether the ownership structure is clean enough to attract future rounds. A cap table with excessive early dilution of founders, missing option pool, or complicated ownership structures can make an otherwise attractive business model uninvestable. Teams should present their cap table clearly and be prepared to model how the current round affects ownership percentages at each subsequent funding stage.
Return Profile
An estimate of the financial return the business can generate for investors, expressed in terms of expected exit valuation, investor multiple, and exit pathway. Investors are typically deploying capital with the expectation of a 5-10x return within 7-10 years. The return profile must be grounded in realistic comparable transactions — what have similar companies sold for, what revenue or EBITDA multiples have recent exits commanded, and what acquirers are active in your category. A return profile that relies on an implausibly high exit valuation or an unrealistically short timeline will not be taken seriously by experienced investors.

Nice to Haves — HealthTech

A funding staircase diagram showing the capital requirements, key milestones, and expected valuation step-ups at each funding stage from current round through exit gives investors a visual representation of the full investment thesis. It signals that the team has thought carefully about the complete path to value creation and not just the immediate financing need.

Comparable transaction analysis — a table of recent acquisitions or IPOs of similar medical device or diagnostic companies showing exit valuations, revenue multiples, and acquirer identity — provides an evidence base for the return profile and demonstrates that the team understands the M&A landscape in their category.

A sensitivity table showing how investor returns change under different exit timing and valuation scenarios — what is the investor multiple if the company exits at 3x revenue vs 5x revenue, or at year 7 vs year 10 — gives investors the tools to evaluate the opportunity under their own assumptions rather than accepting the team's base case.

Nice to Haves — Digital Medicine

Rule of 40 analysis — the sum of revenue growth rate and profit margin, a standard benchmark for SaaS business model health — is an increasingly common metric among digital health investors. A Rule of 40 score above 40 signals that the business is balancing growth and profitability effectively. Early-stage companies will typically be well below 40, but demonstrating awareness of the metric and a credible path toward it signals financial sophistication.

SaaS valuation multiples — digital medicine companies are typically valued on ARR multiples rather than revenue or EBITDA multiples at the early stage. Understanding the current market range for ARR multiples in your category, and being able to explain what drives multiple expansion or compression, is a standard expectation in a digital health investor conversation.

A magic number analysis — measuring the efficiency of sales and marketing spend in generating new ARR — tells investors how capital-efficiently the business can scale its go-to-market motion. A magic number above 0.75 is generally considered healthy for a digital health subscription business and signals that increased investment in sales and marketing will generate proportionate returns.

Return to:

The H-BMC Blocks